These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10414877)

  • 21. Delavirdine: a review of its use in HIV infection.
    Scott LJ; Perry CM
    Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Update on nevirapine: quest for a niche.
    MacDougall DS
    J Int Assoc Physicians AIDS Care; 1997 Sep; 3(9):37-43. PubMed ID: 11364713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cellular proviral HIV type 1 DNA load persists after long-term RT-inhibitor therapy in HIV type 1 infected persons.
    Bruisten SM; Reiss P; Loeliger AE; van Swieten P; Schuurman R; Boucher CA; Weverling GJ; Huisman JG
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1053-8. PubMed ID: 9718120
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modelling the costs of paediatric HIV infection and AIDS: comparison of infected children born to screened and unscreened mothers.
    Sculpher MJ; Gibb D; Ades AE; Ratcliffe J; Duong T
    AIDS; 1998 Jul; 12(11):1371-80. PubMed ID: 9708418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current perspectives on antiretroviral therapy.
    Fletcher CV
    Pharmacotherapy; 1993; 13(6):627-33. PubMed ID: 7508101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness.
    Ratcliffe J; Ades AE; Gibb D; Sculpher MJ; Briggs AH
    AIDS; 1998 Jul; 12(11):1381-8. PubMed ID: 9708419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F; Boucher C; Loveday C; Descamps D; Fauveau V; Izopet J; Jeffries D; Kaye S; Krzyanowski C; Nunn A; Schuurman R; Seigneurin JM; Tamalet C; Tedder R; Weber J; Weverling GJ
    Lancet; 1997 Oct; 350(9083):983-90. PubMed ID: 9329513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between TISS and ICU cost.
    Dickie H; Vedio A; Dundas R; Treacher DF; Leach RM
    Intensive Care Med; 1998 Oct; 24(10):1009-17. PubMed ID: 9840233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced HIV infection treated with zidovudine monotherapy: lifetime values of absolute cost-effectiveness as a pharmacoeconomic reference for future studies evaluating antiretroviral combination treatments. The Osservatorio SIFO sui Farmaci.
    Messori A; Becagli P; Berto V; Trippoli S; Font M; Tosolini F; Venturini F; Martini N
    Ann Pharmacother; 1997 Dec; 31(12):1447-54. PubMed ID: 9416379
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
    Revicki DA; Moyle G; Stellbrink HJ; Barker C
    AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.
    Lacey L; Mauskopf J; Lindrooth R; Pham S; Saag M; Sawyer W
    Pharmacoeconomics; 1999; 15 Suppl 1():23-37. PubMed ID: 10537440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death.
    Currie CJ; Morgan CL; Dixon S; McEwan P; Marchant N; Bearne A; Sharplin P; Peters JR
    Diabetes Res Clin Pract; 2004 Sep; 65(3):267-74. PubMed ID: 15331207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A trial comparing nucleoside monotherapy with sequential therapy with 3 drugs in HIV-infected patients.
    Roca B; Olmos P; Mínguez C; Arnedo A; Usó J; Teruel C; Segarra M; Sáez-Royuela A; Simón E
    Scand J Infect Dis; 1998; 30(4):426-8. PubMed ID: 9817530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. National Prospective Monitoring System Steering Group.
    Beck EJ; Mandalia S; Williams I; Power A; Newson R; Molesworth A; Barlow D; Easterbrook P; Fisher M; Innes J; Kinghorn G; Mandel B; Pozniak A; Tang A; Tomlinson D
    AIDS; 1999 Oct; 13(15):2157-64. PubMed ID: 10546870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. One world, one hope: the cost of providing antiretroviral therapy to all nations.
    Hogg RS; Weber AE; Craib KJ; Anis AH; O'Shaughnessy MV; Schechter MT; Montaner JS
    AIDS; 1998 Nov; 12(16):2203-9. PubMed ID: 9833862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
    Lancet; 1999 Jun; 353(9169):2014-25. PubMed ID: 10376616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.